# GE HealthCare: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

GE HealthCare Technologies Inc. · NASDAQ: GEHC · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/ge-healthcare. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, GE HealthCare: how the business works", with the page URL.

## The 30-second summary

GE HealthCare makes CT, MRI, X-ray and ultrasound scanners, imaging drugs and patient monitors, and it has been a separate company since leaving General Electric in Jan 2023. It earned $20.6 billion of revenue in FY2025, of which $7.0 billion came from servicing machines already installed. Its imaging-drug segment kept $30.1 of segment EBIT per $100 of sales, against $9.6 for scanners (Cityfort calculation from the FY2025 10-K).

## 5 points

- **What it sells:** GE HealthCare sells CT, MRI, X-ray and ultrasound scanners, imaging drugs, patient monitors and service on installed machines, with revenue of $20.6 billion in FY2025. [S1]
- **Who pays it:** In FY2025, hospitals and clinics buying equipment and drugs paid 66.2% of GE HealthCare's revenue, and owners of installed machines paid 33.8% for service contracts and repairs. [S1]
- **What it keeps from $100:** Of every $100 that came in during FY2025, GE HealthCare kept $9.9 as profit for shareholders, a figure that includes $445 million of pension and other non-operating income, while EBITDA was $16.2 per $100 of revenue. [S1]
- **Where the operating profit comes from:** In FY2025, Advanced Visualization Solutions earned $1.18 billion of segment EBIT, Imaging $891 million, Pharmaceutical Diagnostics $872 million and Patient Care Solutions $209 million. [S1]
- **The one thing to watch:** Net debt rose from $5.5 billion at Dec 31, 2025 to $7.1 billion at Sep 30, 2026 after the $2.3 billion Intelerad purchase (Cityfort calculation from the FY2025 10-K and the Q3 FY2026 10-Q), and the company said on Oct 28, 2026 it expects the $945 million SOFIE deal to close in the first half of 2027. [S1, S3, S9]

## What does GE HealthCare sell?

GE HealthCare makes the machines hospitals use to look inside the body: CT and MRI scanners, X-ray and ultrasound. It also sells the drugs injected before some scans, bedside patient monitors and software that stores and reads medical images.

- **Imaging scanners:** CT, MRI, X-ray, mammography and molecular imaging (PET and SPECT) machines. This Imaging segment sold $9.2 billion in FY2025. [S1]
- **Ultrasound and procedure guidance:** Ultrasound machines for general and pregnancy care, and imaging systems that guide surgeons and heart doctors during procedures. Sales were $5.4 billion in FY2025. [S1]
- **Imaging drugs:** Contrast agents and radioactive tracers injected so organs show up clearly on a scan; they also work with other makers' scanners. Sales were $2.9 billion in FY2025. [S1]
- **Patient care equipment:** Bedside monitors, heart tests (ECG), anesthesia machines and newborn care equipment, plus their consumables and service. Sales were $3.1 billion in FY2025. [S1]
- **Service:** Upkeep and repair contracts on machines already installed. Sales of services were $7.0 billion of the $20.6 billion FY2025 revenue. [S1]

## Who pays GE HealthCare?

- **Hospitals and clinics buying equipment and drugs (66.2% of revenue):** Public, private, academic and government hospitals and health systems, and researchers, in more than 160 countries. Product sales were $13.7 billion in FY2025. [S1]
- **Owners of installed machines paying for service (33.8% of revenue):** Service contracts and repairs brought in $7.0 billion in FY2025, up 5.6% from FY2024. [S1]
- **Who funds the hospitals:** Hospitals are paid by government programs such as Medicare and Medicaid and by private health plans; the 10-K says these payers have become more cost-conscious. [S1]
- **Customer concentration:** No single customer was more than 10% of revenue in FY2023, FY2024 or FY2025, or more than 10% of money owed to the company. [S1]

## Where the money went (FY2025)

1. Hospitals and clinics paid $20.6 billion for machines, drugs, software and service in FY2025.
2. Making the products and delivering the service cost $12.4 billion.
3. Sales teams, administration and research took another $5.5 billion.
4. Pension and other income added $445 million; interest and income taxes took $1.05 billion.
5. About $2.1 billion was left for GE HealthCare's shareholders, after $70 million for minority partners.

Sources: S1.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2023 | 19,552 | 3,045 | 15.6% | 1,385 | 7.1% | 3.03 | 2,101 | 387 | 1,714 | S26, S1 |
| FY2024 | 19,672 | 3,205 | 16.3% | 1,993 | 10.1% | 4.34 | 1,955 | 401 | 1,554 | S2 |
| FY2025 | 20,625 | 3,341 | 16.2% | 2,084 | 10.1% | 4.55 | 1,987 | 482 | 1,505 | S1 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.
- FY2023: Net income to common stockholders, the base of diluted EPS; net income attributable to GE HealthCare was $1,568 million before a $183 million deemed dividend on a redeemable minority stake.

## Balance sheet (as of Sep 30, 2026, US$ million)

Net debt was $7.1 billion at Sep 30, 2026, about 3.6 times FY2025 cash from operations of $2.0 billion (Cityfort calculation from the Q3 FY2026 10-Q and the FY2025 10-K). [S3, S1, S9]

| Item | Value |
| --- | --- |
| Total debt | 9,973 |
| Cash and investments | 2,854 |
| Net debt (debt minus cash) | 7,119 |
| Net worth (shareholders' money) | 11,614 |
| Debt to equity (times) | 0.86 |

- Net debt is total borrowings of $9.97 billion minus $2.85 billion of cash, cash equivalents and restricted cash (Cityfort calculation from the Q3 FY2026 10-Q). It was $5.5 billion at Dec 31, 2025 (Cityfort calculation from the FY2025 10-K), before the $2.3 billion Intelerad purchase in March 2026.
- Goodwill and other intangible assets were $17.0 billion, or 44.2% of total assets of $38.4 billion at Sep 30, 2026 (Cityfort calculation from the Q3 FY2026 10-Q).
- The Q3 FY2026 earnings release states $3.5 billion of access to revolving credit lines at Sep 30, 2026.
- Long-term pension and other employee benefit obligations (non-current compensation and benefits) were $5.1 billion at Sep 30, 2026.

## Who owns GE HealthCare? (as of Mar 9, 2026)

One class of stock with one vote per share, and no controlling holder. Directors and executive officers (18 people) held 1,631,245 shares including units and options, 0.36% of the Jan 28, 2026 share count (Cityfort calculation from the 2026 proxy statement and the FY2025 10-K). [S19, S1, S3]

- Officers and directors (as a group), shares: 0.36%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (452,137,831 shares at Oct 21, 2026 (Q3 FY2026 10-Q cover), against 455,749,767 at Jan 28, 2026 (FY2025 10-K cover). It is the only class.) | 452.14 | 1 | — | — | Yes | S3, S1 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 11.5% | — | Jan 30, 2025 | Proxy figure (52,535,829 shares), based on a Schedule 13G/A filed Jan 30, 2025. | S19 |
| BlackRock, Inc. | 7.9% | — | Nov 8, 2024 | Proxy figure (36,271,390 shares), based on a Schedule 13G/A filed Nov 8, 2024. | S19 |
| Dodge & Cox | 6.8% | — | Feb 13, 2026 | Proxy figure (31,211,229 shares), based on a Schedule 13G/A filed Feb 13, 2026. | S19 |
| Capital Research Global Investors | 5.5% | — | Nov 13, 2025 | Proxy figure (24,972,556 shares), based on a Schedule 13G filed Nov 13, 2025. | S19 |

## What could go wrong

### Patient Care Solutions profit

PCS segment EBIT fell from $383 million in FY2023 to $209 million in FY2025, and the segment lost $26 million in Q2 FY2026 before earning $68 million in Q3. [S1, S4, S9]

What to watch: PCS sales and segment EBIT in the FY2026 results, the first under new PCS chief Neal Sandy.

### Tariffs and cost inflation

The company said tariffs cut FY2025 operating income by about $245 million. In July 2026 it cited about $250 million of inflation from memory chips, oil, freight and other components. [S1, S10]

What to watch: Tariff costs, tariff refunds and cost inflation reported with the FY2026 results.

### China sales

China region revenue fell 15% in FY2024 and 4.6% in FY2025. The 10-K says China uses volume-based buying to hold down healthcare costs. [S1, S2]

What to watch: China region revenue in the region table of each 10-Q.

### Debt after acquisitions

Net debt rose from $5.5 billion at Dec 31, 2025 to $7.1 billion at Sep 30, 2026 (Cityfort calculation from the FY2025 10-K and the Q3 FY2026 10-Q), after the $2.3 billion Intelerad purchase. The company said on Oct 28, 2026 that the $945 million SOFIE deal is expected to close in the first half of 2027. [S1, S3, S9]

What to watch: Total borrowings and cash in the FY2026 10-K.

### Raw materials and single suppliers

The company relies on helium, iodine and rare earth minerals, and on several single- or sole-source suppliers with no alternative yet identified. Management said a PDx supplier issue hurt Q1 FY2026 profit and has since been resolved. [S1, S12]

What to watch: Supply problems named in the earnings releases.

### Lawsuit and a possible IRS tax assessment

A lawsuit alleges GE HealthCare and other companies funded an Iraqi terrorist group through Iraqi health-ministry contracts. According to the Q3 FY2026 10-Q, GE informed the company that the IRS may assert a material amount of additional taxes and penalties for 2016 to 2020. Any such amount is to be allocated between GE and GE HealthCare under their Tax Matters Agreement. [S3]

What to watch: The legal and indemnity notes in the FY2026 10-K.

### Leadership changes

Controller George Newcomb was named interim CFO on Jul 23, 2026; Jay Saccaro stayed with the company through Aug 14, 2026, and a permanent CFO is being sought. Patient Care Solutions got a new chief on Nov 16, 2026. [S11, S9]

What to watch: An 8-K naming a permanent CFO.

## What to watch

Next: Q4 FY2026 results (expected, based on the Feb 4, 2026 date for Q4 FY2025), Feb 4, 2027 (expected).

- **FY2026 results against the company's ranges:** Management said on Oct 28, 2026 that it expects FY2026 adjusted EPS of $4.95 to $5.05 and free cash flow of $1.6 billion or more. The Q4 FY2026 release will show the reported figures.
- **Patient Care Solutions under a new chief:** Neal Sandy has led PCS since Nov 16, 2026. Segment EBIT was a $26 million loss in Q2 FY2026 and $68 million in Q3.
- **A permanent CFO:** Controller George Newcomb was named interim CFO on Jul 23, 2026; Jay Saccaro stayed with the company through Aug 14, 2026. An 8-K would name a permanent CFO.
- **SOFIE deal and debt:** The company said on Oct 28, 2026 that it expects the $945 million SOFIE purchase to close in the first half of 2027. Net debt was $7.1 billion at Sep 30, 2026 (Cityfort calculation from the Q3 FY2026 10-Q).

## Sources

- S1: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm (published Feb 4, 2026)
- S2: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000005/gehc-20241231.htm (published Feb 13, 2025)
- S3: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000059/gehc-20260930.htm (published Oct 28, 2026)
- S4: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000046/gehc-20260630.htm (published Jul 29, 2026)
- S5: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000031/gehc-20260331.htm (published Apr 29, 2026)
- S6: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000053/gehc-20250930.htm (published Oct 29, 2025)
- S7: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000049/gehc-20250630.htm (published Jul 30, 2025)
- S8: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000014/gehc-20250331.htm (published Apr 30, 2025)
- S9: Q3 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000058/release3q26earnings.htm (published Oct 28, 2026)
- S10: Q2 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000045/release2q26earnings.htm (published Jul 29, 2026)
- S11: 8-K of Jul 23, 2026: CFO transition and preliminary Q2 FY2026 revenue (Ex. 99). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000039/form8-kex99_72126.htm (published Jul 23, 2026)
- S12: Q1 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000030/release1q26earnings.htm (published Apr 29, 2026)
- S13: Q4 and FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000006/release4q25earnings.htm (published Feb 4, 2026)
- S14: Q3 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000052/release3q25earnings.htm (published Oct 29, 2025)
- S15: Q2 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000048/release2q25earnings.htm (published Jul 30, 2025)
- S16: Q1 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000013/release1q25earnings.htm (published Apr 30, 2025)
- S17: Q4 and FY2024 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239325000004/release4q24earnings.htm (published Feb 13, 2025)
- S18: Q3 FY2024 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239324000049/release3q24earnings.htm (published Oct 30, 2024)
- S19: 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000021/gehc-20260318.htm (published Mar 19, 2026)
- S23: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239324000050/0001932393-24-000050-index.htm (published Oct 30, 2024)
- S24: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239324000044/0001932393-24-000044-index.htm (published Jul 31, 2024)
- S25: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/0001932393-24-000034-index.htm (published Apr 30, 2024)
- S26: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1932393/000193239324000013/0001932393-24-000013-index.htm (published Feb 6, 2024)
